Skip to main content
Fig. 4 | Molecular Medicine

Fig. 4

From: Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1

Fig. 4

The risk signature predicted response to common antitumor drugs in the TCGA-LUAD cohort. A Comparison of immune checkpoint gene expression between the high- and low-risk groups. B–D Calculation of the immunophenoscore B and the sensitivity to anti-CTLA4 C and anti-PD1/PDL1/PDL2 D immunotherapy for the two subgroups. E–J. Half inhibitory concentrations (IC50) were compared between high- and low-risk groups for cisplatin (E), docetaxel (F), gemcitabine (G), paclitaxel (H), erlotinib (I), and gefitinib (J)

Back to article page

Molecular Medicine

ISSN: 1528-3658